Duke receives approval to initiate NPC-1C Phase I trial for advanced pancreatic and colorectal cancer

Neogenix Oncology, Inc. (Neogenix) announced today that researchers at Duke University Medical Center have received approval to move forward with a Phase I trial of the company's lead therapeutic antibody, NPC-1C, in patients with advanced stage pancreatic or colorectal cancer. Duke joins Johns Hopkins Hospital which is already conducting the Phase I trial of NPC-1C. In addition to Johns Hopkins, North Shore - LIJ has also enrolled patients on this multi-center study.

“I am pleased to be participating in the clinical evaluation of this agent in a study population with limited treatment options”

NPC-1C is a novel, chimeric monoclonal antibody intended for the treatment of advanced pancreatic and colorectal cancer, and is the first of the Neogenix pipeline of antibodies that target specific cancers. Pre-clinical studies have demonstrated that NPC-1C specifically targets pancreatic and colorectal cancer sparing healthy tissue.

"We are pleased to partner with the investigators at Duke University Medical Center as they join Johns Hopkins on this study. We look forward to fostering the relationships with both of these prestigious medical establishments for future Neogenix therapeutic development. There is a serious need for new therapies for life-threatening cancers, especially pancreatic cancer where very few treatment options exist. Having a treatment that would target the cancer specifically and spare healthy organs would represent a significant advancement in the treatment of this disease", said Neogenix Chief Executive Officer, Philip M. Arlen, MD.

"I am pleased to be participating in the clinical evaluation of this agent in a study population with limited treatment options," said Michael A. Morse, M.D., associate professor of medicine at Duke University Medical Center, Principal Investigator on the study.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
How AI is advancing mammographic density-based breast cancer risk prediction